🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heidelberg
Clinical trial register · Germany

Clinical Trials in Heidelberg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Heidelberg50 AstraZeneca33 Janssen Research & Development, LLC27 Merck Sharp & Dohme LLC18 Hoffmann-La Roche17
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Heidelberg

627 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
NCT03981276Hereditary Spastic Paraplegia
Dr. Rebecca Schule
Observational
2,000
Bonn, Erlangen, Essen, Göttingen, Heidelberg, Lübeck, Magdeburg, München
2019-10-14
Active, closed
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsVusolimogene Oderparepvec·Cemiplimab
Replimune, Inc.
Phase 2
231
Berlin, Essen, Hamburg, Heidelberg, München, Tübingen
2019-10-08
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Heidelberg, Dresden, Bad Nauheim
2019-10-03
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Erlangen, Essen, Hamburg, Heidelberg, Mainz
2019-10-03
Recruiting
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
NCT04094454Anal Cancer
Juergen Debus
Not applicable
60
Heidelberg
2019-10-01
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Gauting, Heidelberg
2019-10-01
Active, closed
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414Multiple Myeloma
DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib
Celgene
Phase 1/2
424
Freiburg im Breisgau, Hamburg, Heidelberg, München, Würzburg
2019-09-30
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Heidelberg, Greifswald, Mainz, Homburg, Leipzig, Donaueschingen, Dresden, Hamburg
2019-09-23
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Heidelberg, Ludwigshafen, Mainz, Mannheim, Würzburg
2019-09-17
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Cologne, Heidelberg, Munich, Ulm, Wuppertal
2019-08-20
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan
Bristol-Myers Squibb
Phase 3
839
Dresden, Essen, Hamburg, Hanover, Heidelberg, Marburg, Munich
2019-08-05
Recruiting
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447Glioblastoma
DrugsAZD1390·Troriluzole·Paxalisib·CCNU
Global Coalition for Adaptive Research
Phase 2/3
2,250
Cologne, Frankfurt, Heidelberg, Mannheim, Regensburg, Tübingen
2019-07-30
Recruiting
The Sarcoma Biology and Outcome Project
NCT04758325Sarcoma, Malignant Mesenchymoma, Sarcoma of Bone and Connective Tissue
Prof. Dr. Richard F Schlenk
Observational
3,000
Heidelberg
2019-07-23
Active, closed
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
DrugDcr-Phxc
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
75
Bonn, Heidelberg
2019-07-09
Active, closed
IMPEDE and IMPEDE-FX Embolization Plug Registry
NCT04044443Peripheral Vascular Embolization
Shape Memory Medical, Inc.
Observational
108
Dresden, Heidelberg, Kiel, Leipzig, München, Nuremberg, Stuttgart, Würzburg
2019-07-09
Active, closed
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219Renal Cell Carcinoma
DrugsCabozantinib·Yervoy·Opdivo·Ipilimumab
Exelixis
Phase 3
855
Heidelberg, Tübingen, Frankfurt am Main, Münster, Mainz, Jena, Dresden
2019-06-25
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Heidelberg
2019-06-13
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
415
Heidelberg, Mainz, Berlin, Bochum, Buxtehude, Cologne, Dresden, Essen
2019-06-04
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Bad Krozingen, Bonn, Dresden, Hamburg, Heidelberg, Leipzig, Munich, Rostock
2019-05-28
Active, closed
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
NCT03639051COPD
Nuvaira, Inc.
Not applicable
464
Heidelberg
2019-05-23
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
DrugsAnzu-cel·Opdivo·Nivolumab
Immatics US, Inc.
Phase 1/2
375
Heidelberg, Munich, Würzburg, Bonn, Mainz, Dresden, Berlin, Hamburg
2019-05-14
Recruiting
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
NCT04219202Sarcoma,Soft Tissue
University Hospital Heidelberg
Not applicable
64
Heidelberg
2019-05-09
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Berlin, Bonn, Chemnitz, Cologne, Freiburg im Breisgau, Heidelberg, Leipzig, Lübeck
2019-04-29
Recruiting
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
NCT05906407Early-Stage Breast Cancer, Neoadjuvant Therapy
German Cancer Research Center
Observational
2,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2019-04-19
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
DrugBaricitinib
Eli Lilly and Company
Phase 3
190
Berlin, Hamburg, Heidelberg, Sankt Augustin, Tübingen
2019-04-05
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
DrugPumitamig
AstraZeneca
Phase 3
140
Berlin, Essen, Heidelberg
2019-04-02
Active, closed
Automatic PredICtion of Edema After Stroke
NCT04057690Stroke, Acute, Brain Edema
University Hospital Tuebingen
Observational
1,687
Berlin, Bonn, Bremen, Düsseldorf, Hamburg, Hanover, Heidelberg, Leipzig
2019-04-01
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Dresden, Göttingen, Halle, Hanover, Heidelberg, Homburg, Regensburg, Trier
2019-03-06
Recruiting
Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
NCT03758521Succinic Semialdehyde Dehydrogenase Deficiency
Boston Children's Hospital
Observational
55
Heidelberg
2019-01-15
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
DrugsEribulin·Trastuzumab deruxtecan·Nab-paclitaxel·Capecitabine
Daiichi Sankyo
Phase 3
557
Heidelberg, Munich
2018-12-27
Active, closed
Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels
NCT03720704Peripheral Vascular Diseases
W.L.Gore & Associates
Observational
280
Heidelberg, Münster
2018-12-18
Recruiting
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT03767075Advanced Solid Tumor
DrugsFutibatinib·Amivantamab·Atezolizumab
Vall d'Hebron Institute of Oncology
Phase 2
1,000
Heidelberg, Dresden
2018-12-10
Recruiting
Register Kardialer Computertomographie
NCT03815123Evaluation of CT in Coronary Artery Stenosis
Das Radiologische Zentrum
Observational
10,000
Heidelberg
2018-12-06
Recruiting
Pulmonary Hemodynamics During Exercise - Research Network
NCT03954574Pulmonary Circulation Diseases
Medical University of Graz
Observational
1,500
Cologne, Giessen, Greifswald, Heidelberg, Würzburg
2018-12-01
Active, closed
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Edwards Lifesciences
Not applicable
1,247
Bad Oeynhausen, Cologne, Dresden, Essen, Giessen, Hamburg, Heidelberg, Leipzig
2018-11-30
Recruiting
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas
NCT03396718Head-and-neck Squamous Cell Carcinoma
Technische Universität Dresden
Not applicable
304
Tübingen, Essen, Dresden, Berlin, Frankfurt am Main, Freiburg im Breisgau, Heidelberg, München
2018-11-29
Active, closed
Personalized Exercise Oncology
NCT04328038Cancer, Health Behavior
University Hospital Heidelberg
Observational
800
Heidelberg
2018-11-26
Recruiting
Molecularly Aided Stratification for Tumor Eradication Research
NCT05852522Rare Cancers, Multiomics
German Cancer Research Center
Observational
10,000
Heidelberg
2018-11-11
Active, closed
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
NCT03235245Unresectable Stage III Melanoma, Stage IV Melanoma
DrugsBinimetinib·Encorafenib·Ipilimumab·Nivolumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
271
Heidelberg, Mainz, Würzburg
2018-10-30
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg
2018-09-27
Recruiting
Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies
NCT04083937Prostate Cancer
University Hospital Heidelberg
Not applicable
897
Heidelberg
2018-09-12
Recruiting
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
NCT03676504Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
DrugsFludarabine·Cyclophosphamide
University Hospital Heidelberg
Phase 1/2
68
Heidelberg
2018-09-07
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Erlangen, Munich, Frankfurt am Main, Kassel
2018-08-28
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
DrugsAlectinib·Vinorelbine·Pemetrexed·Gemcitabine
Hoffmann-La Roche
Phase 3
257
Chemnitz, Georgsmarienhütte, Heidelberg, Immenhausen
2018-08-16
Active, closed
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973Metastatic Urothelial Cancer
DrugsDomvanalimab·Zimberelimab·Avelumab·Enfortumab Vedotin
Gilead Sciences
Phase 2
502
Duisburg, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Herne, Jena, Koblenz
2018-08-13
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Heidelberg, Frankfurt am Main, Münster, Selters, Kiel, Bonn, Hamburg, Hanover
2018-08-09
Active, closed
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT03513614Node-positive Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
1,500
Essen, Georgsmarienhütte, Heidelberg, Karlsruhe, Wuppertal
2018-08-07
Recruiting
Registry Study of Proton Radiotherapy in Lymphoma
NCT04613388Mediastinal Lymphoma
University Hospital Heidelberg
Observational
200
Heidelberg
2018-08-01
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt, Hamburg, Heidelberg
2018-07-19
Recruiting
Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
NCT04732910Cystic Fibrosis
Charite University, Berlin, Germany
Observational
500
Berlin, Giessen, Hanover, Heidelberg
2018-07-01
Recruiting
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989Post Operative Pain
AtriCure, Inc.
Observational
5,000
Heidelberg
2018-06-29
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
DrugsBacillus Calmette-Guerin·Durvalumab
AstraZeneca
Phase 3
1,018
Berlin, Cologne, Duisburg, Hanover, Heidelberg, Marburg, Mettmann, Mühlheim An Der Ruhr
2018-05-14
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
DrugsRucaparib·Opdivo·Nivolumab
pharmaand GmbH
Phase 3
1,097
Dessau, Düsseldorf, Heidelberg, Mannheim, Traunstein
2018-05-14
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
Berlin, Bielefeld, Heidelberg, Munich, Würzburg
2018-04-23
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Augsburg, Berlin, Dresden, Frankfurt, Frankfurt am Main, Hamburg, Hanover, Heidelberg
2018-04-13
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 2/3
714
Heidelberg, Tübingen, Quedlinburg, Buxtehude, Cologne, Erfurt, Essen, Hanover
2018-04-11
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,336
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main
2018-04-09
Recruiting
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
NCT03949972Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Idiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter
Observational
500
Cologne, Aachen, Berlin, Bonn, Dachau, Erlangen, Essen, Heidelberg
2018-04-01
Recruiting
Post-Market BTVA Registry
NCT03318406Emphysema or COPD
Uptake Medical Technology, Inc.
Observational
300
Bamberg, Berlin, Essen, Gauting, Halle, Heidelberg, Hemer, Immenhausen
2018-03-22
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Mannheim, Augsburg, Berlin, Essen, Hamburg, Heidelberg
2018-01-26
Recruiting
Natural History of Wilson Disease
NCT03334292Wilson Disease
Yale University
Observational
300
Heidelberg
2017-12-18
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Düsseldorf, Hamburg, Heidelberg, Kirchheim, Münster, Nürtingen
2017-12-18
Active, closed
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
NCT03334617Non-Small Cell Lung Cancer
DrugsVistusertib·Danvatirsen·Ceralasertib·Cediranib Maleate
AstraZeneca
Phase 2
528
Berlin, Esslingen a.N., Großhansdorf, Heidelberg
2017-12-18
Active, closed
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03319667Plasma Cell Myeloma
DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide
Sanofi
Phase 3
475
Berlin, Frankfurt am Main, Heidelberg, Tübingen
2017-12-07
Recruiting
Evaluation of Optical Coherence Tomography in Dentistry
NCT03753256Dental Caries, Tooth Demineralization
University of Heidelberg Medical Center
Not applicable
20
Heidelberg
2017-12-04
Recruiting
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
NCT03383978Glioblastoma
DrugEzabenlimab
Johann Wolfgang Goethe University Hospital
Phase 1
42
Heidelberg, Mannheim, Mainz, Frankfurt
2017-12-01
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
Chemnitz, Essen, Frankfurt am Main, Heidelberg, Münster
2017-10-26
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München
2017-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
Chemnitz, Gauting, Heidelberg, Wiesbaden
2017-09-22
Active, closed
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
NCT03161353Breast Cancer
DrugsPerjeta·Herceptin·Tamoxifen·Pertuzumab
MedSIR
Phase 2
377
Essen, Halle, Heidelberg, Leipzig, Munich, München
2017-06-26
Recruiting
MED-EL HEARING SOLUTIONS (MEHS): AN OBSERVATIONAL STUDY
NCT05668338Hearing Loss
MED-EL Elektromedizinische Geräte GesmbH
Observational
100
Bochum, Dresden, Frankfurt, Heidelberg, München, Oldenburg, Rostock, Tübingen
2017-06-26
Recruiting
CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
NCT05652569Metastatic Breast Cancer
German Cancer Research Center
Observational
5,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2017-06-12
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsTremelimumab·Abraxane·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
REDUCE LAP-HF TRIAL II
NCT03088033Heart Failure
Corvia Medical
Not applicable
608
Bad Nauheim, Berlin, Düsseldorf, Freiburg im Breisgau, Göttingen, Hamburg, Heidelberg, Leipzig
2017-06-01
Active, closed
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608Carcinoma, Non-Small-Cell Lung
DrugsCrizotinib·Lorlatinib
Pfizer
Phase 3
296
Dresden, Heidelberg, Homburg - Saar, Regensburg
2017-04-27
Active, closed
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840Lymphoma, Mantle Cell
DrugsAcalabrutinib·Bendamustine·Rituximab
Acerta Pharma BV
Phase 3
635
Heidelberg, München, Münster, Nordrhein-Westfalen, Ravensburg, Rheinland-Pfalz, Ulm
2017-04-05
Active, closed
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Recruiting
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
NCT02986516Chordoma
Italian Sarcoma Group
Not applicable
100
Dresden, Essen, Heidelberg
2017-03-16
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
500
Berlin, Cologne, Dresden, Heidelberg
2017-03-07
Active, closed
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
NCT02808780Ulcerative Colitis
Janssen Biotech, Inc.
Observational
535
Berlin, Dessau Roblau, Halle, Hamburg, Heidelberg, Kiel, Leipzig, Ludwigshafen
2016-12-16
Recruiting
Sickle-cell Disease Registry of the GPOH
NCT03327428Sickle Cell Disease
University Hospital Heidelberg
Observational
1,000
Heidelberg
2016-12-15
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
DrugsDarzalex·Iberdomide·Velcade·Carfilzomib
Celgene
Phase 1/2
466
Dresden, Düsseldorf, Hamburg, Heidelberg, Tübingen, Würzburg
2016-10-14
Active, closed
Clinical Performance of B-Lite® Light Weight Breast Implant
NCT02777476Breast Implants
G&G Biotechnology Ltd.
Not applicable
120
Heidelberg
2016-10
Active, closed
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
NCT02766543Prostate Cancer
Profound Medical Inc.
Not applicable
150
Cologne, Heidelberg
2016-09-21
Recruiting
Heidelberg Study on Diabetes and Complications
NCT03022721Diabetes Complications
Heidelberg University
Observational
500
Heidelberg
2016-09
Active, closed
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016Ovarian Neoplasms
DrugNiraparib
Tesaro, Inc.
Phase 3
733
Aachen, Berlin, Essen, Fürth, Göttingen, Heidelberg, Hildesheim, Mannheim
2016-07-11
Active, closed
Neoadjuvant L19IL2/L19TNF- Pivotal Study
NCT02938299Malignant Melanoma
DrugsL19IL2·Onfekafusp alfa
Philogen S.p.A.
Phase 3
214
Dresden, Hanover, Heidelberg, Kiel, Leipzig, Berlin, Tübingen, Augsburg
2016-07-01
Active, closed
STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program
NCT02825264Open Angle Glaucoma
iSTAR Medical
Observational
70
Dortmund, Heidelberg, München, Rostock
2016-07
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
Heidelberg, Berlin
2016-06-16
Active, closed
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
NCT03469674Endometrial Cancer Stage I, Endometrial Cancer Stage II
Leiden University Medical Center
Phase 3
550
Berlin, Düsseldorf, Essen, Heidelberg, Lübeck, Münich, Tübingen
2016-06-10
Active, closed
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
NCT02650401Solid Tumors, CNS Tumors
DrugEntrectinib
Hoffmann-La Roche
Phase 1/2
69
Heidelberg
2016-05-03
Active, closed
Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
NCT02999074Breast Cancer
German Cancer Research Center
Not applicable
183
Heidelberg
2016-01-22
Active, closed
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
NCT02637687Solid Tumors Harboring NTRK Fusion
DrugLarotrectinib
Bayer
Phase 1/2
154
Heidelberg, Stuttgart, Berlin
2015-12-16
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
DrugCeritinib
Novartis Pharmaceuticals
Phase 4
233
Regensburg, Cologne, Essen, Heidelberg, Würzburg
2015-12-11
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
DrugEntrectinib
Hoffmann-La Roche
Phase 2
534
Berlin, Cologne, Göttingen, Heidelberg
2015-11-19
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,126
Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster
2015-11-02
Recruiting
Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.
NCT05852418Amyotrophic Lateral Sclerosis
Ambulanzpartner Soziotechnologie APST GmbH
Observational
25,000
Berlin, Bochum, Bonn, Dresden, Essen, Göttingen, Hanover, Heidelberg
2015-10-30
Active, closed
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
NCT02562235Hypertension, Pulmonary
DrugRiociguat
Bayer
Phase 3
24
Heidelberg, Ulm, Berlin
2015-10-29
Active, closed
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
NCT02375204Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma
DrugsPegylated G-CSF·Ifosfamide·G-Csf·CDDP
Alliance for Clinical Trials in Oncology
Phase 3
420
Dresden, Berlin, Düsseldorf, Essen, Hamburg, Heidelberg, Koblenz, Marburg
2015-08-06
Active, closed
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282Non-Small-Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
1,118
Aachen, Bad Berka, Berlin, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Hemer
2015-07-21
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib
Eli Lilly and Company
Phase 3
545
Gerlingen, Heidelberg, Cologne, Chemnitz, Halle, Großhansdorf, Berlin
2015-05-06
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Cologne, Jena, Heidelberg
2015-03-06
Active, closed
Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones
NCT03025763Craniosynostosis
Icahn School of Medicine at Mount Sinai
Observational
2,145
Heidelberg
2015-01-13
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
DrugBispecific
Partner Therapeutics, Inc.
Phase 2
250
Hamburg, Heidelberg
2015-01
Active, closed
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736Prostatic Neoplasms
DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone
Aragon Pharmaceuticals, Inc.
Phase 3
982
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Münster, Nürtingen, Wuppertal
2014-11-26
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
DrugsErlotinib·Abemaciclib
Eli Lilly and Company
Phase 3
453
Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg
2014-10-03
Recruiting
Myocardial Infarction Registry
NCT06128317Acute Coronary Syndrome
University Hospital Heidelberg
Observational
2,500
Heidelberg
2014-08-01
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
University Hospital Tuebingen
Observational
13,500
Böblingen, Freiburg im Breisgau, Heidelberg, Karlsruhe, Mannheim, Nürtingen, Tübingen, Ulm
2014-06
Active, closed
HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
NCT01915615Hypertrophic Cardiomyopathy
University of Virginia
Observational
2,750
Berlin, Heidelberg, Stuttgart
2014-04
Active, closed
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
NCT02633943Transfusion-dependent Beta-Thalassemia
Genetix Biotherapeutics Inc.
Observational
66
Hanover, Heidelberg
2014-01
Active, closed
Zimmer POLAR Persona - TKA (EMEA Study)
NCT02337244Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis
Zimmer, GmbH
Observational
777
Braunschweig, Heidelberg
2013-11-18
Active, closed
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
NCT01983241Pulmonary Emphysema in Alpha-1 PI Deficiency
DrugProlastin-C
Grifols Therapeutics LLC
Phase 3
345
Heidelberg, Marburg, Essen, Homburg Saar
2013-11
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
Augsburg, Bad Berka, Cologne, Dortmund, Gerlingen, Großhansdorf, Halle, Heidelberg
2013-09-25
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
700
Berlin, Dresden, Essen, Giessen, Heidelberg, Homburg/Saar, Magdeburg, Marburg
2013-09-09
Active, closed
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Freiburg im Breisgau, Heidelberg, Mannheim, Sigmaringen, Ulm, Erlangen, Memmingen, Munich
2013-04-29
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Essen, Hanover, Heidelberg, Lübeck, Münster, Tübingen
2013-03-18
Active, closed
Survivorship of Attune Primary Total Knee Prosthesis
NCT01754363Noninflammatory Degenerative Joint Disease
DePuy International
Not applicable
1,542
Bad Abbach, Heidelberg
2013-02-01
Active, closed
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
NCT01357668Juvenile Idiopathic Arthritis
Bristol-Myers Squibb
Observational
800
Bad Bramstedt, Berlin, Freiburg im Breisgau, Hamburg, Heidelberg
2013-01-30
Active, closed
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512Multiple Myeloma
Bristol-Myers Squibb
Observational
2,555
Heidelberg, Hamm, Aschaffenburg, Berlin, Dresden, Magdeburg, München, Rostock
2012-06-13
Recruiting
Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
NCT02270476Cystic Fibrosis Lung Disease
Heidelberg University
Observational
200
Heidelberg, Giessen, Hanover, Lübeck
2011-12
Recruiting
International (Pediatric) Peritoneal Biobank
NCT01893710Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
Heidelberg University
Observational
500
Heidelberg, Berlin, Cologne, Essen, Hamburg, Marburg
2011-02-01
Recruiting
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
NCT03188874Acute Myeloid Leukemia (AML)
Technische Universität Dresden
Observational
15,000
Baden-Baden, Heidelberg, Mannheim, Schwäbisch Hall, Sindelfingen, Stuttgart, Winnenden, Augsburg
2010-09
Recruiting
Pilot Project on Interdisciplinary Therapy of Obesity
NCT01344525Obesity, Weight Loss
University of Hohenheim
Not applicable
480
Heidelberg, Stuttgart, Tübingen
2009-05
Recruiting
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
NCT00903110IGF1 Deficiency
Esteve Pharmaceuticals, S.A.
Observational
500
Erlangen, Heidelberg, Homburg, Magdeburg, Oldenburg
2008-12-09
Active, closed
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
NCT00626990Brain and Central Nervous System Tumors
DrugsTemodal·Temodar·Temozolomide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
751
Bamberg, Bonn, Hanover, Heidelberg, Regensburg, Tübingen
2007-12
Recruiting
ColoCare Study - Colorectal Cancer Cohort
NCT02328677Colorectal Cancer
University of Utah
Observational
5,000
Heidelberg
2007-03
Recruiting
Heidelberg Registry for Hip and Knee Joint Implants and Revisions
NCT06850818Osteoarthritis, Arthroplasty
University Hospital Heidelberg
Observational
10,000
Heidelberg
2007-01-01
Rows per page Showing 501–627 of 627
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/heidelberg?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 627 of those studies with a site in Heidelberg.

How many clinical trials are recruiting in Heidelberg?

333 of the 627 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 16 have not yet opened recruitment, 272 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.